Pain Disengagement Training (Open Pilot)
Launched by MASSACHUSETTS GENERAL HOSPITAL · Mar 5, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new approach to help people with chronic musculoskeletal pain, which is pain that lasts for more than three months. The researchers want to see if a writing-based program can help individuals manage their pain better, especially those who tend to worry a lot about their pain. The study will look at how easy it is to recruit participants, how well they accept and stick to the program, and how satisfied they are with the treatment.
To be eligible for this trial, participants need to be adults aged 18 or older who have been experiencing moderate to severe pain and have high levels of pain-related worry. They should also be able to write or type for at least 30 minutes. Participants will need to have received care at Massachusetts General Hospital and be comfortable writing in English. It’s important to note that individuals with serious mental health issues or those who have recently changed their medical treatment won’t be able to participate. This trial is currently not recruiting participants, but it aims to provide valuable insights into how writing can help manage chronic pain.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Outpatient adults (i.e., greater than or equal to 18)
- • 2. Has self reported chronic musculoskeletal pain (i.e., pain persisting for at least 3 months)
- • 3. Pain score greater than or equal to 4 (moderate) on the Numerical Rating Scale
- • 4. Pain catastrophizing score greater than or equal to 20 on Pain Catastrophizing Scale
- • 5. Willingness to engage in a writing-based intervention and self-reported ability to write or type for at least 30 minutes in a sitting
- • 6. Received care at Massachusetts General Hospital
- • 7. English verbal and writing fluency
- Exclusion Criteria:
- • 1. Clinically significant change in therapy or medication in the past 3 months
- • 2. Severe untreated mental health condition (e.g., psychosis)
- • 3. Active suicidality with history of plan or current intent
- • 4. Serious illness expected to worsen in the next 6 months (e.g., cancer)
- • 5. Untreated substance use problem that, per patient's self-report, would interfere with the ability to complete the intervention.
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Katherine McDermott, PhD
Principal Investigator
Massachusetts General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported